Cardax (CDXI) 10-Q 15 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 15, 2020
Document And Entity Information
Entity Registrant Name	CARDAX, INC.
Entity Central Index Key	0001544238
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		772,098
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 51,191	$ 19,303
Accounts receivable	103,591	205,768
Inventories	1,116,560	1,177,831
Deposits and other assets	3,063	2,066
Prepaid expenses	168,252	181,093
Total current assets	1,442,657	1,586,061
INTANGIBLE ASSETS, net	420,912	420,373
RIGHT TO USE LEASED ASSETS	9,606	12,488
TOTAL ASSETS	1,873,175	2,018,922
CURRENT LIABILITIES
Accrued payroll and payroll related expenses, current portion	3,788,788	3,687,376
Accounts payable and accrued expenses	1,570,898	1,544,402
Fees payable to directors	418,546	418,546
Accrued separation costs, current portion	9,750	9,000
Current portion of related party notes payable	575,000	575,000
Related party convertible notes payable	901,220	651,721
Convertible notes payable, net of discount	430,546	358,289
Employee settlement	50,000	50,000
Lease liability, current portion	9,606	11,527
Derivative liability on convertible notes payable	619,508	827,314
Total current liabilities	8,373,862	8,133,175
NON-CURRENT LIABILITIES
Related party notes payable, less of current portion	1,000,000	1,000,000
Accrued separation costs, less current portion	80,635	83,635
Lease liability, less current portion		961
Total non-current liabilities	1,080,635	1,084,596
COMMITMENTS AND CONTINGENCIES
Total liabilities	9,454,497	9,217,771
STOCKHOLDERS' DEFICIT
Preferred Stock - $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2020, and December 31, 2019, respectively
Common stock - $0.001 par value; 400,000,000 shares authorized, 762,098 and 687,564 shares issued and outstanding as of March 31,2020, and December 31, 2019, respectively	762	688
Additional paid-in-capital	60,457,139	59,836,818
Accumulated deficit	(68,039,223)	(67,036,355)
Total stockholders' deficit	(7,581,322)	(7,198,849)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,873,175	$ 2,018,922

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	762,098	687,564
Common stock, shares outstanding	762,098	687,564

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
REVENUES, net	$ 142,813	$ 164,972
COST OF GOODS SOLD	62,995	104,180
GROSS PROFIT	79,818	60,792
OPERATING EXPENSES:
Salaries and wages	373,292	404,809
Professional fees	222,316	241,368
Selling, general, and administrative expenses	168,413	291,569
Stock based compensation	177,813	180,375
Research and development	35,282	45,672
Depreciation and amortization	8,733	11,262
Total operating expenses	985,849	1,175,055
Loss from operations	(906,031)	(1,114,263)
OTHER INCOME (EXPENSE):
Gain on modification of debt instruments	354,791
Change in fair value of derivative liability	(3,667)
Interest expense	(447,961)	(21,157)
Total other (expense) income, net	(96,837)	(21,157)
Loss before the provision for income taxes	(1,002,868)	(1,135,420)
PROVISION FOR INCOME TAXES
NET LOSS	$ (1,002,868)	$ (1,135,420)
NET LOSS PER SHARE
Basic	$ (1.43)	$ (1.69)
Diluted	$ (1.43)	$ (1.69)
SHARES USED IN CALCULATION OF NET LOSS PER SHARE
Basic	700,879	670,260
Diluted	700,879	670,260

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-In-Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 670	$ 58,407,257	$ (61,943,318)	$ (3,535,391)
Balance, shares at Dec. 31, 2018	669,967
Common stock grants to independent directors	$ 2	87,498		87,500
Common stock grants to independent directors, shares	2,303
Common stock grants to service providers		6,375		6,375
Common stock grants to service providers, shares	187
Stock based compensation - options		86,500		86,500
Restricted stock issuances	$ 2	44,998		45,000
Restricted stock issuances, shares	1,501
Extinguishment of derivative liability upon repayment of convertible note
Net loss			(1,135,420)	(1,135,420)
Balance at Mar. 31, 2019	$ 674	58,632,628	(63,078,738)	(4,445,436)
Balance, shares at Mar. 31, 2019	673,958
Balance at Dec. 31, 2019	$ 688	59,836,818	(67,036,355)	(7,198,849)
Balance, shares at Dec. 31, 2019	687,564
Common stock grants to independent directors	$ 3	18,747		18,750
Common stock grants to independent directors, shares	3,125
Stock based compensation - options		84,063		84,063
Warrants granted to independent directors		75,000		75,000
Common stock grant to convertible note holders	$ 71	434,641		434,712
Common stock grant to convertible note holders, shares	71,409
Issuance of warrants attached to a convertible note		2,777		2,777
Beneficial conversion feature issued on convertible notes		141,391		141,391
Revaluation of notes payable discounts due to modification of conversion price		(214,498)		(214,498)
Extinguishment of derivative liability upon repayment of convertible note		78,200		78,200
Net loss			(1,002,868)	(1,002,868)
Balance at Mar. 31, 2020	$ 762	$ 60,457,139	$ (68,039,223)	$ (7,581,322)
Balance, shares at Mar. 31, 2020	762,098

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,002,868)	$ (1,135,420)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	8,733	11,262
Amortization of debt discount	297,656
Stock based compensation	177,813	180,375
Change in fair value of derivative liability	3,667
Gain on modification of debt instruments	(354,791)
Changes in assets and liabilities:
Accounts receivable	85,385	21,743
Inventories	61,271	57,378
Deposits and other assets	(997)
Prepaid expenses	12,841	914
Accrued payroll and payroll related expenses	101,412	35,662
Accounts payable and accrued expenses	43,288	(373,962)
Accrued separation costs	(2,250)	(2,250)
Net cash used in operating activities	(568,840)	(1,204,298)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in intangible assets	(9,272)	(11,100)
Net cash used in investing activities	(9,272)	(11,100)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuances of convertible notes payable	770,000
Payment of debt issuance costs	(10,000)
Repayment of convertible notes principal	(150,000)
Proceeds from the issuances of related party notes payable		1,000,000
Proceeds from the issuance of common stock		45,000
Net cash provided by financing activities	610,000	1,045,000
NET INCREASE (DECREASE) IN CASH	31,888	(170,398)
CASH AT THE BEGINNING OF THE PERIOD	19,303	243,753	$ 243,753
CASH AT THE END OF THE PERIOD	51,191	73,355	$ 19,303
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	116,341	10,967
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Settlement of receivables with payables	16,792	49,956
Right to use assets funded through leases	2,882	30,813
Discounts recognized on notes payable at issuance	765,732
Extinguishment of derivative liability upon repayment of convertible note	78,200
Revaluation of notes payable discounts due to modification of conversion price	$ 534,623

Company Background

Company Background	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Company Background	NOTE 1 – COMPANY BACKGROUND The Company’s predecessor, Cardax Pharmaceuticals, Inc. (“Holdings”), was incorporated in the State of Delaware on March 23, 2006. Cardax, Inc. (the “Company”) (OTCQB:CDXI) is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. The Company also has a commercial business unit that markets dietary supplements for inflammatory health. CDX-101, the Company’s astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. The Company’s pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. ZanthoSyn® is a physician recommended astaxanthin dietary supplement for inflammatory health. The Company sells ZanthoSyn® primarily through wholesale and e-commerce channels. The safety and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA. Going concern matters The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred net losses of $1,002,868 and $1,135,420 for the three-months ended March 31, 2020 and 2019, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $68,039,223 as of March 31, 2020, and has had negative cash flows from operating activities since inception. The Company expects that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers, and anticipates further losses in the development of its consumer business. The Company also plans to advance the research and development of its pharmaceutical candidates and anticipates further losses in the development of its pharmaceutical business. The Company’s ability to access the capital markets is unknown during the coronavirus disease 2019 (“COVID-19”) pandemic, which may limit or prevent the funding of its operations and related obligations. As a result of these and other factors, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company needs to raise additional capital to carry out its business plan. During the three-months ended March 31, 2020, the Company raised $770,000 in gross proceeds through the issuance of debt securities. The Company filed a registration statement on Form S-1 on August 14, 2019, as amended September 27, 2019 and November 22, 2019, for a proposed $15 million public offering of common stock and warrants; however, there can be no assurance that the proposed public offering will be consummated. The Company’s continued ability to raise capital through future equity and debt securities issuances is unknown, especially during the COVID-19 pandemic. If the Company is unable to obtain adequate capital, the Company may be required to cease operations or substantially curtail its ongoing and planned commercial activities. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited interim financial information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2020 and 2019. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 30, 2020. Revenue from contracts with customers Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the three-months ended: March 31, 2020 March 31, 2019 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 142,813 $ 164,972 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale. Notes payable The Company issued various notes payable to related and non-related parties. These notes payable included original issue discounts, detachable warrants, conversion features, beneficial conversion features, and debt issuance costs. ● Original issue discounts. Interest and Imputation of Interest ● Detachable warrants. Debt ● Conversion features Derivatives and Hedging; Embedded Derivatives ● Beneficial conversion features. Debt ● Debt issuance costs. Debt Stock issuance costs Stock issuance costs related to financing are accounted for as a reduction in stock proceeds in accordance with ASC No. 340-10, Other Assets and Deferred Costs Other significant accounting policies There have been no other material changes to our significant accounting policies during the three-months ended March 31, 2020, as compared to the significant accounting policies described in our Annual Report. Recently adopted accounting pronouncements In November 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-08, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) Recently issued accounting pronouncements In December 2019, the FASB Issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the condensed consolidated financial statements. Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventories	NOTE 3 – INVENTORIES Inventories consist of the following as of: March 31, 2020 December 31, 2019 Raw materials $ 763,800 $ 763,800 Finished Goods 352,760 414,031 Total inventories $ 1,116,560 $ 1,177,831 As of March 31, 2020 and December 31, 2019, $763,800 in raw materials were held at the manufacturer’s facility for future production. Additionally, as of March 31, 2020 and December 31, 2019, $320,125 and $407,756, respectively, in finished goods were held at the manufacturer’s facility for shipment.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	NOTE 4 – INTANGIBLE ASSETS, net Intangible assets, net, consists of the following as of: March 31, 2020 December 31, 2019 Patents $ 614,003 $ 614,003 Less accumulated amortization (340,814 ) (332,081 ) 273,189 281,922 Patents pending 147,723 138,451 Total intangible assets, net $ 420,912 $ 420,373 Patents are amortized using the straight-line method over a period of fifteen years. Amortization expense was $8,733 and $11,262 for the three-months ended March 31, 2020 and 2019, respectively. The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved. The Company has 29 issued patents, including 14 in the U.S. and 15 outside the U.S. and one patent pending outside the U.S. that will expire between 2023 and 2028, subject to patent term extensions. The Company also has four additional patents pending that if issued would extend patent coverage in the U.S. and outside the U.S. to 2039-2041.

Accrued Separation Costs

Accrued Separation Costs	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Separation Costs	NOTE 5 –ACCRUED SEPARATION COSTS On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. As of March 31, 2020, $90,385 remains outstanding of which $9,750 is due within one-year and is reflected as a current liability.

Related Party Notes Payable

Related Party Notes Payable	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Notes Payable	NOTE 6 – RELATED PARTY NOTES PAYABLE Notes payable consisted of the following as of: March 31, 2020 December 31, 2019 (Unaudited) Inventory financing. $ 1,000,000 $ 1,000,000 Officer loan. 75,000 75,000 Promissory note. 500,000 500,000 Total notes payable 1,575,000 1,575,000 Less current portion (575,000 ) (575,000 ) Long term notes payable $ 1,000,000 $ 1,000,000 Interest expense The Company incurred interest charges of $45,593 and $19,973 during the three-months ended March 31, 2020 and 2019, respectively, on these notes payable. The aggregate amount of accrued and unpaid interest on these notes payable was $63,143 and $10,192 as of March 31, 2020 and 2019, respectively. Maturities Future maturities of notes payable are as follows as of March 31: 2020 $ 575,000 2021 - 2022 1,000,000 $ 1,575,000

Related Party Convertible Notes

Related Party Convertible Notes Payable	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Convertible Notes Payable	NOTE 7 – RELATED PARTY CONVERTIBLE NOTES PAYABLE Related party convertible notes payable consisted of the following as of: March 31, 2020 December 31, 2019 (Unaudited) Convertible note 2019-02. $ 815,217 $ 815,217 Convertible note 2019-07. 217,391 217,391 Officer convertible note. 100,000 100,000 Total notes payable 1,132,608 1,132,608 Less original issue discounts (82,608 ) (82,608 ) Related party convertible notes payable, net 1,050,000 1,050,000 Less discounts for conversion rights, beneficial conversion features, and detachable warrants (297,360 ) (693,316 ) Plus amortization of discounts 148,580 295,037 Total convertible notes payable, net $ 901,220 $ 651,721 Discounts Total discounts (original issue discounts plus discounts for conversion rights, beneficial conversion features, and detachable warrants) of $379,968 are amortized using the interest method, which resulted in amortization recorded as interest expense of $112,446 for the three-months ended March 31, 2020, with total accumulated amortization equal to $148,580 as of March 31, 2020. In February 2020, the Company adjusted the conversion price of certain related party convertible notes payable in accordance with their terms, which triggered modification accounting and resulted in a gain on these convertible notes of $258,903. Interest expense The Company incurred interest charges of $24,020 during the three-months ended March 31, 2020 on these related party convertible notes payable. The aggregate amount of accrued and unpaid interest on these related party convertible notes payable was $8,183 as of March 31, 2020. Maturities Future maturities of notes payable are as follows as of March 31: 2020 $ 1,132,608 $ 1,132,608

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 8 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following as of: March 31, 2020 (Unaudited) December 31, 2019 Convertible note 2019-01. $ - $ 150,000 Convertible note 2019-03. 108,696 108,696 March 31, 2020 December 31, 2019 (Unaudited) Convertible note 2019-04. 54,348 54,348 Convertible note 2019-05. 27,174 27,174 Convertible note 2019-06. 27,174 27,174 Convertible note 2019-08. 108,696 108,696 Convertible note 2019-09. 27,174 27,174 Convertible note 2019-10. 16,304 16,304 Convertible note 2020-01. 10,870 - Convertible note 2020-02. 262,500 - Convertible note 2020-03. 52,631 - Convertible note 2020-04. 250,000 - Convertible note 2020-05. 250,000 - Total notes payable 1,195,567 519,566 Less original issue discounts (85,567 ) (29,566 ) Convertible notes payable, net 1,110,000 490,000 Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants (830,397 ) (253,675 ) Plus amortization of discounts 150,943 121,964 Total convertible notes payable, net $ 430,546 $ 358,289

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	NOTE 9 – DERIVATIVE FINANCIAL INSTRUMENTS The Company has identified the embedded derivatives related to the convertible notes described in Notes 7 and 8. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of these derivative liabilities as of the inception date of those convertible notes and each subsequent reporting date. The Company estimates the fair value of these derivative liabilities using the Black-Scholes valuation model. The initial value is used in the determination of a note discount with each subsequent change in fair value as a component of operations. The range of fair value assumptions used for derivative financial instruments during the three-months ended March 31, 2020, were as follows: Dividend yield 0.0% Risk-free rate 0.17% - 1.43% Volatility 183% - 190% Expected term 1 year Volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of valuation for the expected term of the derivative liabilities to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. For the three-months ended March 31, 2020, the Company recognized total derivative liabilities and convertible note discounts based on their fair value at the convertible notes’ inception and/or adjustment dates. These derivative liabilities were subsequently revalued at $619,508 as of March 31, 2020, which resulted in a gain of $3,667 on the change in value of these derivative liabilities. During the three months ended March 31, 2020, there was a derivative liability of $78,200 that expired upon repayment of an outstanding convertible note, which was recorded as an adjustment to additional paid in capital. The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 March 31, 2020 $ - $ - $ 619,508

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 10 – STOCKHOLDERS’ DEFICIT Reverse Stock Split On January 15, 2020, the Company effected a 200-for-1 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock. The Reverse Stock Split did not change the number of shares of common stock authorized for issuance, the par value of the common stock, or any other terms of the common stock. No fractional shares were issued in the Reverse Stock Split and any remaining share fractions were rounded up to the next whole share. Under the terms and conditions of outstanding options, warrants, and other convertible securities, the number of underlying shares of common stock and the exercise prices or conversion prices thereof were proportionately adjusted for the Reverse Stock Split. All share and per share amounts reported in the condensed consolidated financial statements reflect the Reverse Stock Split. Self-directed stock issuance 2019 During the year ended December 31, 2019, the Company sold securities in a self-directed offering to existing stockholders of the Company in the aggregate amount of $245,000, respectively, at $60 per unit. Each $60 unit consisted of 2 shares of restricted common stock (8,169 shares) and a five-year warrant to purchase 1 share of restricted common stock (4,085 warrant shares) at $40 per share. Shares outstanding As of March 31, 2020 and December 31, 2019, the Company had a total of 762,098 and 687,564, respectively, shares of common stock outstanding.

Stock Grants

Stock Grants	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stock Grants	NOTE 11 – STOCK GRANTS Director stock grants During the three-months ended March 31, 2020 and 2019, the Company granted its independent directors an aggregate of 3,125 and 2,303 shares of restricted common stock, respectively. These shares were fully vested upon issuance. The expense recognized for these grants based on the grant date fair value was $18,750 and $87,500 for the three-months ended March 31, 2020 and 2019, respectively. The decrease in expense related to director stock grants was due to certain independent directors’ election to receive their compensation in the form of warrants effective as of the quarter ended March 31, 2020. Consultant stock grants On March 31, 2019, the Company granted consultants 187 shares of restricted common stock valued at $34 per share. On June 30, 2019, the Company granted consultants 188 shares of restricted common stock valued at $25 per share. On September 30, 2019, the Company granted consultants 187 shares of restricted common stock valued at $17.80 per share. On December 31, 2019, the Company granted consultants 188 shares of restricted common stock valued at $12 per share. These shares were fully vested upon issuance. There was no such grant during the three-months ended March 31, 2020. The Company recognized $0 and $6,375 in stock-based compensation related to these grants during the three-months ended March 31, 2020 and 2019, respectively.

Stock Option Plans

Stock Option Plans	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Option Plans	NOTE 12 – STOCK OPTION PLANS On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares reserved under this plan upon adoption was 152,101. On April 16, 2015, the majority stockholder of the Company approved an increase in the shares reserved under this plan by 75,000 shares. On December 4, 2018, the stockholders of the Company approved an increase in the shares reserved under this plan by an additional 25,000 shares and authorized the annual increase of the shares reserved under this plan on January 1st of each year, at the discretion of the Board of Directors, by up to such number of shares that is equal to four percent (4%) of the shares of common stock issued and outstanding as of December 31st of the previous calendar year. Accordingly, effective as of January 1, 2020, the shares reserved under this plan were increased by 27,000 shares. An aggregate of 279,101 shares of common stock were reserved for issuance under this plan as March 31, 2020. Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years. A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2019 202,537 $ 80.13 4.52 $ 987,064 Exercisable January 1, 2019 185,837 $ 82.13 4.10 $ 967,064 Canceled (291 ) Granted - Exercised - Forfeited - Outstanding December 31, 2019 202,246 $ 80.14 3.52 $ - Exercisable December 31, 2019 192,108 $ 81.32 3.26 $ - Canceled - Granted - Exercised - Forfeited - Outstanding March 31, 2020 202,246 $ 80.14 3.27 $ - Exercisable March 31, 2020 193,513 $ 81.16 3.05 $ - The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on March 31, 2020, based on a valuation of the Company’s stock for that day. A summary of the Company’s non-vested options for the three-months ended March 31, 2020 and year ended December 31, 2019, are presented below: Non-vested at January 1, 2019 16,700 Granted - Vested (6,271 ) Canceled (291 ) Non-vested at December 31, 2019 10,138 Granted - Vested (1,405 ) Canceled - Non-vested at March 31, 2020 8,733 The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options issued were as follows for the: Three-months ended March 31, 2020 Year ended December 31, 2019 Dividend yield 0.0 % 0.0 % Risk-free rate 2.38% - 3.04 % 2.38% - 3.04 % Volatility 214% - 226 % 214% - 226 % Expected term 3 – 7 years 3 – 7 years Volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period. Stock based compensation The Company recognized stock-based compensation expense related to options during the: Three-months ended March 31 2020 2019 Amount Amount Service provider compensation $ 44,375 $ 44,375 Employee compensation 39,688 42,125 Total $ 84,063 $ 86,500

Warrants

Warrants	3 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 13 – WARRANTS The following is a summary of the Company’s warrant activity: Warrants Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value Outstanding January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Exercisable January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Canceled - Granted 20,985 Exercised - Expired (94,577 ) Outstanding December 31, 2019 516,748 $ 24.60 1.86 $ - Exercisable December 31, 2019 516,748 $ 24.60 1.86 $ - Canceled - Granted 13,356 Exercised - Expired (83,068 ) Outstanding March 31, 2020 447,036 $ 23.81 2.15 $ - Exercisable March 31, 2020 447,036 $ 23.81 2.15 $ - The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The expected volatility is calculated based on the historical volatility of the Company. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed. Convertible note warrants During the three-months ended March 31, 2020, warrants to purchase 600 shares of common stock at $7.50 to $10.00 per share were issued in connection with the issuance of convertible notes. During the year ended December 31, 2019, warrants to purchase 16,900 shares of common stock at $14 to $40 per share were issued in connection with the issuance of convertible notes. These warrants were immediately vested and expire in five years. The value of the warrants was recorded as a discount on the convertible notes in the aggregate amount of $69,498 and $125,545 during the three-months ended March 31, 2020 and the year ended December 31, 2019, respectively. Director warrant grants During the three-months ended March 31, 2020, the Company granted its independent directors warrants to purchase an aggregate of 12,756 shares of common stock at $6.00 per share. These warrants were immediately vested and expire in ten years. During the three-months ended March 31, 2020, the Company recognized stock-based compensation expense related to these warrants in the aggregate amount of $75,000. During the year ended December 31, 2019, the Company did not recognize any stock-based compensation expense related to warrants. Warrant expiration During the three-months ended March 31, 2020, warrants to purchase an aggregate of 83,068 shares of common stock expired. During the year ended December 31, 2019, warrants to purchase an aggregate of 94,577 shares of common stock expired.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 14 – INCOME TAXES The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. The effective tax rate for the three-months ended March 31, 2020 and 2019, differs from the statutory rate of 21% as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets. The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes Uncertain tax positions The Company is subject to taxation in the United States and three state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events. As of March 31, 2020 and December 31, 2019, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	NOTE 15 – BASIC AND DILUTED NET LOSS PER SHARE The following table sets forth the computation of the Company’s basic and diluted net loss per share for: Three-months ended March 31, 2020 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,002,868 ) 700,879 $ (1.43 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (1,002,868 ) 700,879 $ (1.43 ) Three-months ended March 31, 2019 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,135,420 ) 670,260 $ (1.69 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (1,135,420 ) 670,260 $ (1.69 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended: March 31, 2020 March 31, 2019 (Unaudited) (Unaudited) Commons stock underlying convertible notes 443,410 - Common stock underlying options 202,246 202,537 Common stock underlying warrants 447,036 499,041 Total common stock equivalents 1,092,692 701,578

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	NOTE 16 – LEASES Manoa Innovation Center The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $8,989 and $9,100 for the three-months ended March 31, 2020 and 2019, respectively. Fleet lease In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases require monthly payments of $1,619 for three years. These leases convert to month-to-month leases in January 2021 unless terminated. The Company terminated one lease in August of 2019, which reduced the monthly payments to $1,002. Total lease expense under this agreement was $3,754 and $5,959 for the three-months ended March 31, 2020 and 2019, respectively. Right-to-use leased asset and liability The Company recognized a right-to-use leased asset and liability for the fleet leases. The balance of this right-to-use asset and liability was $9,606 and $30,813 as of March 31, 2020 and 2019, respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 17 – SUBSEQUENT EVENTS The Company evaluated all material events through the date the financials were ready for issuance and identified the following for additional disclosure. Impact of COVID-19 The COVID-19 pandemic is a worldwide health crisis that is adversely affecting the economies and financial markets of many countries and may have short-term and long-term adverse effects on the Company’s business, financial condition, and results of operations that cannot be predicted as the global pandemic continues to evolve. The Company’s sales, receivables, and access to financing, have been adversely affected during the pandemic. As a result of the COVID-19 pandemic, the CARES Act was signed into law, part of which provided for the Paycheck Protection Program (“PPP”) under the U.S. Small Business Administration. On April 22, 2020, the Company received a PPP loan for $211,300. Under the terms of the program, up to 100% of the loan amount may be forgiven if certain terms and conditions are met. The unforgiven amount, if any, matures in April 2022 and accrues interest at 1% per annum with principal and interest payments starting in November 2020. Management expects that a portion if not all of this loan will be forgiven. Convertible Promissory Notes On May 14, 2020, the Company issued a convertible note payable in the amount $500,000, with an original issue discount of $40,000 in exchange for $460,000. This note accrues interest at 10% per annum and matures on May 14, 2021. This note and accrued interest may convert into shares of common stock at the conversion price then in effect (initially $9.75 per share, subject to adjustment) any time at the holder’s option. The conversion price is subject to adjustment upon the issuance of the Company’s common stock or securities convertible into common stock at a price per share less than the then prevailing conversion price, other than specified exempt issuances. 10,000 shares of common stock were issued as a commitment fee in connection with the purchase of this note. On May 14, 2020, the Company fully repaid a convertible note dated March 16, 2020 in the principal amount of $250,000 together with accrued and unpaid interest thereon.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited interim financial information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2020 and 2019. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 30, 2020.
Revenue from Contracts with Customers	Revenue from contracts with customers Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the three-months ended: March 31, 2020 March 31, 2019 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 142,813 $ 164,972 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale.
Notes Payable	Notes payable The Company issued various notes payable to related and non-related parties. These notes payable included original issue discounts, detachable warrants, conversion features, beneficial conversion features, and debt issuance costs. ● Original issue discounts. Interest and Imputation of Interest ● Detachable warrants. Debt ● Conversion features Derivatives and Hedging; Embedded Derivatives ● Beneficial conversion features. Debt ● Debt issuance costs. Debt
Stock Issuance Costs	Stock issuance costs Stock issuance costs related to financing are accounted for as a reduction in stock proceeds in accordance with ASC No. 340-10, Other Assets and Deferred Costs
Other Significant Accounting Policies	Other significant accounting policies There have been no other material changes to our significant accounting policies during the three-months ended March 31, 2020, as compared to the significant accounting policies described in our Annual Report.
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements In November 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-08, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606)
Recently Issued Accounting Pronouncements	Recently issued accounting pronouncements In December 2019, the FASB Issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the condensed consolidated financial statements.
Reclassifications	Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedule of Revenues Disaggregated by Revenue Source and Geographical Location	The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the three-months ended: March 31, 2020 March 31, 2019 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 142,813 $ 164,972

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following as of: March 31, 2020 December 31, 2019 Raw materials $ 763,800 $ 763,800 Finished Goods 352,760 414,031 Total inventories $ 1,116,560 $ 1,177,831

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	Intangible assets, net, consists of the following as of: March 31, 2020 December 31, 2019 Patents $ 614,003 $ 614,003 Less accumulated amortization (340,814 ) (332,081 ) 273,189 281,922 Patents pending 147,723 138,451 Total intangible assets, net $ 420,912 $ 420,373

Related Party Notes Payable (Ta

Related Party Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Notes Payable	Notes payable consisted of the following as of: March 31, 2020 December 31, 2019 (Unaudited) Inventory financing. $ 1,000,000 $ 1,000,000 Officer loan. 75,000 75,000 Promissory note. 500,000 500,000 Total notes payable 1,575,000 1,575,000 Less current portion (575,000 ) (575,000 ) Long term notes payable $ 1,000,000 $ 1,000,000
Schedule of Related Party Future Maturities of Notes Payable	Future maturities of notes payable are as follows as of March 31: 2020 $ 575,000 2021 - 2022 1,000,000 $ 1,575,000

Related Party Convertible Not_2

Related Party Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Convertible Notes Payable	Related party convertible notes payable consisted of the following as of: March 31, 2020 December 31, 2019 (Unaudited) Convertible note 2019-02. $ 815,217 $ 815,217 Convertible note 2019-07. 217,391 217,391 Officer convertible note. 100,000 100,000 Total notes payable 1,132,608 1,132,608 Less original issue discounts (82,608 ) (82,608 ) Related party convertible notes payable, net 1,050,000 1,050,000 Less discounts for conversion rights, beneficial conversion features, and detachable warrants (297,360 ) (693,316 ) Plus amortization of discounts 148,580 295,037 Total convertible notes payable, net $ 901,220 $ 651,721
Schedule of Related Party Future Maturities of Convertible Notes Payable	Future maturities of notes payable are as follows as of March 31: 2020 $ 1,132,608 $ 1,132,608

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	NOTE 8 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following as of: March 31, 2020 (Unaudited) December 31, 2019 Convertible note 2019-01. $ - $ 150,000 Convertible note 2019-03. 108,696 108,696 March 31, 2020 December 31, 2019 (Unaudited) Convertible note 2019-04. 54,348 54,348 Convertible note 2019-05. 27,174 27,174 Convertible note 2019-06. 27,174 27,174 Convertible note 2019-08. 108,696 108,696 Convertible note 2019-09. 27,174 27,174 Convertible note 2019-10. 16,304 16,304 Convertible note 2020-01. 10,870 - Convertible note 2020-02. 262,500 - Convertible note 2020-03. 52,631 - Convertible note 2020-04. 250,000 - Convertible note 2020-05. 250,000 - Total notes payable 1,195,567 519,566 Less original issue discounts (85,567 ) (29,566 ) Convertible notes payable, net 1,110,000 490,000 Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants (830,397 ) (253,675 ) Plus amortization of discounts 150,943 121,964 Total convertible notes payable, net $ 430,546 $ 358,289
Schedule of Future Maturities of Convertible Notes Payable	Future maturities of notes payable are as follows as of March 31: 2020 $ 1,195,567 $ 1,195,167

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value Assumptions Related to Option Issued	The Company estimates the fair value of these derivative liabilities using the Black-Scholes valuation model. The initial value is used in the determination of a note discount with each subsequent change in fair value as a component of operations. The range of fair value assumptions used for derivative financial instruments during the three-months ended March 31, 2020, were as follows: Dividend yield 0.0% Risk-free rate 0.17% - 1.43% Volatility 183% - 190% Expected term 1 year The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 March 31, 2020 $ - $ - $ 619,508

Stock Option Plans (Tables)

Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2019 202,537 $ 80.13 4.52 $ 987,064 Exercisable January 1, 2019 185,837 $ 82.13 4.10 $ 967,064 Canceled (291 ) Granted - Exercised - Forfeited - Outstanding December 31, 2019 202,246 $ 80.14 3.52 $ - Exercisable December 31, 2019 192,108 $ 81.32 3.26 $ - Canceled - Granted - Exercised - Forfeited - Outstanding March 31, 2020 202,246 $ 80.14 3.27 $ - Exercisable March 31, 2020 193,513 $ 81.16 3.05 $ -
Schedule of Non-vested Shares Granted Under Stock Option Plan	A summary of the Company’s non-vested options for the three-months ended March 31, 2020 and year ended December 31, 2019, are presented below: Non-vested at January 1, 2019 16,700 Granted - Vested (6,271 ) Canceled (291 ) Non-vested at December 31, 2019 10,138 Granted - Vested (1,405 ) Canceled - Non-vested at March 31, 2020 8,733
Schedule of Fair Value Assumptions	The range of fair value assumptions related to options issued were as follows for the: Three-months ended March 31, 2020 Year ended December 31, 2019 Dividend yield 0.0 % 0.0 % Risk-free rate 2.38% - 3.04 % 2.38% - 3.04 % Volatility 214% - 226 % 214% - 226 % Expected term 3 – 7 years 3 – 7 years
Schedule of Recognized Stock Based Compensation Expense	The Company recognized stock-based compensation expense related to options during the: Three-months ended March 31 2020 2019 Amount Amount Service provider compensation $ 44,375 $ 44,375 Employee compensation 39,688 42,125 Total $ 84,063 $ 86,500

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Stock Warrants Activity	The following is a summary of the Company’s warrant activity: Warrants Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value Outstanding January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Exercisable January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Canceled - Granted 20,985 Exercised - Expired (94,577 ) Outstanding December 31, 2019 516,748 $ 24.60 1.86 $ - Exercisable December 31, 2019 516,748 $ 24.60 1.86 $ - Canceled - Granted 13,356 Exercised - Expired (83,068 ) Outstanding March 31, 2020 447,036 $ 23.81 2.15 $ - Exercisable March 31, 2020 447,036 $ 23.81 2.15 $ -

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for: Three-months ended March 31, 2020 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,002,868 ) 700,879 $ (1.43 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (1,002,868 ) 700,879 $ (1.43 ) Three-months ended March 31, 2019 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,135,420 ) 670,260 $ (1.69 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (1,135,420 ) 670,260 $ (1.69 )
Schedule of Shares of Common Stock Equivalents Were Excluded from the Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended: March 31, 2020 March 31, 2019 (Unaudited) (Unaudited) Commons stock underlying convertible notes 443,410 - Common stock underlying options 202,246 202,537 Common stock underlying warrants 447,036 499,041 Total common stock equivalents 1,092,692 701,578

Company Background (Details Nar

Company Background (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Net losses	$ (1,002,868)	$ (1,135,420)
Accumulated deficit	(68,039,223)		$ (67,036,355)
Proceeds from issuance of debt securities	$ 770,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)
Accounting Policies [Abstract]
Payment of stock issuance costs	$ 157,811

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source and Geographical Location (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total revenue	$ 142,813	$ 164,972
United States [Member]
Total revenue	$ 142,813	$ 164,972

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 763,800	$ 763,800
Inventory, finished goods	$ 352,760	$ 414,031

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 763,800	$ 763,800
Finished goods	352,760	414,031
Total inventories	$ 1,116,560	$ 1,177,831

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)PatentApplicationsVehicle	Mar. 31, 2019USD ($)
Patent, amortization period	15 years
Amortization expense | $	$ 8,733	$ 11,262
Patents, units | PatentApplications	29
Patents expiration date	Patents will expire between 2023 and 2028
Number of patent application pending | Vehicle	4
Number of patent application pending, description	The Company also has four patents pending to extend patent coverage in the U.S. and outside the U.S. to 2039-2041.
United States [Member]
Patents, units | PatentApplications	14
Outside the U.S. [Member]
Patents, units | Vehicle	15

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 614,003	$ 614,003
Less accumulated amortization	(340,814)	(332,081)
Patents, Total	273,189	281,922
Patents pending	147,723	138,451
Total intangible assets, net	$ 420,912	$ 420,373

Accrued Separation Costs (Detai

Accrued Separation Costs (Details Narrative) - Separation Agreement [Member] - USD ($)	Mar. 31, 2020	Aug. 09, 2016
Accrued compensation expenses	$ 90,385	$ 118,635
Due Within One-Year [Member]
Accrued compensation expenses	$ 9,750

Related Party Notes Payable (De

Related Party Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Interest charges	$ 45,593	$ 19,973
Notes Payable [Member]
Accrued and payable	$ 63,143	$ 10,192

Related Party Notes Payable - S

Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Total notes payable	$ 1,575,000	$ 1,575,000
Less current portion	(575,000)	(575,000)
Long term notes payable	1,000,000	1,000,000
Inventory Financing [Member]
Total notes payable	1,000,000	1,000,000
Officer Loan [Member]
Total notes payable	75,000	75,000
Promissory Note [Member]
Total notes payable	$ 500,000	$ 500,000

Related Party Notes Payable -_2

Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) (Parenthetical) - USD ($)	Jun. 26, 2019	May 20, 2019	Jan. 11, 2019	Jul. 10, 2019
Inventory Financing [Member]
Line of credit			$ 1,000,000
Line of credit facility, interest rate			12.00%
Inventory Financing [Member] | Minimum [Member]
Ownership percentage			5.00%
Officer Loan [Member]
Debt instrument description	On June 26, 2019, the Company borrowed $75,000 from the Chief Executive Officer of the Company with principal and interest due on August 26, 2019, which was subsequently extended to December 31, 2019. This note accrues interest at the rate of 4.5% per annum and is unsecured.
Officer Loan [Member] | Chief Executive Officer [Member]
Loan borrowed	$ 75,000
Debt instrument, interest rate	4.50%
Promissory Note [Member]
Loan borrowed				$ 100,000
Debt instrument description		This note accrues interest at the rate of 12% per annum, is unsecured, and originally matured on August 20, 2019, which was subsequently extended to June 30, 2020.
Debt instrument, interest rate				12.00%
Note payable		$ 400,000
Promissory Note [Member] | Minimum [Member]
Ownership percentage		5.00%

Related Party Notes Payable -_3

Related Party Notes Payable - Schedule of Related Party Future Maturities of Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Total	$ 1,050,000	$ 1,050,000
Related Party Notes Payable [Member]
2020	575,000
2021
2022	1,000,000
Total	$ 1,575,000

Related Party Convertible Not_3

Related Party Convertible Notes Payable (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 29, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Original issue discount		$ 82,608		$ 82,608
Gain on convertible notes	$ 95,888
Interest charges incurred		45,593	$ 19,973
Related Party Convertible Note Payable [Member]
Original issue discount		379,968
Interest expense		112,446
Accumulated amortization		148,580
Gain on convertible notes	$ 258,903
Interest charges incurred		24,020
Interest accrued and payable		$ 8,183

Related Party Convertible Not_4

Related Party Convertible Notes Payable - Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Oct. 16, 2019	Jul. 19, 2019
Total notes payable	$ 1,132,608	$ 1,132,608
Less original issue discounts	(82,608)	(82,608)
Total	1,050,000	1,050,000
Less discounts for conversion rights, beneficial conversion features, and detachable warrants	(297,360)	(693,316)
Plus amortization of discounts	148,580	295,037
Total convertible notes payable, net	901,220	651,721
Convertible Note 2019 - 02 [Member]
Total notes payable	815,217	815,217
Less original issue discounts				$ (65,217)
Convertible Note 2019 - 07 [Member]
Total notes payable	217,391	217,391
Less original issue discounts			$ (17,391)
Officer Convertible Note [Member]
Total notes payable	$ 100,000	$ 100,000

Related Party Convertible Not_5

Related Party Convertible Notes Payable - Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Nov. 15, 2019	Nov. 08, 2019	Oct. 16, 2019	Jul. 19, 2019	Mar. 31, 2020	Dec. 31, 2019
Original issue discount					$ 82,608	$ 82,608
Convertible Note 2019 - 02 [Member]
Convertible notes payable issued				$ 815,217
Original issue discount				65,217
Exchange of convertible notes payable				$ 750,000
Debt instrument, interest rate				8.00%
Debt instrument, maturity date				Jun. 30, 2020
Debt instrument, conversion price				$ 24	$ 4.27	$ 14
Debt instrument, discount offering price percentage				25.00%
Adjusted exercise price per share					$ 4.27	$ 14
Convertible Note 2019 - 02 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock				7,500
Warrants price per share				$ 24
Additional discount on convertible note					$ 234,300	$ 582,533
Convertible Note 2019 - 02 [Member] | Minimum [Member]
Convertible notes payable issued				$ 5,000,000
Convertible Note 2019 - 07 [Member]
Convertible notes payable issued			$ 217,391
Original issue discount			17,391
Exchange of convertible notes payable			$ 200,000
Debt instrument, interest rate			8.00%
Debt instrument, maturity date			Jun. 30, 2020
Debt instrument, conversion price			$ 24		$ 4.27	$ 14
Debt instrument, discount offering price percentage		25.00%
Adjusted exercise price per share					$ 4.27	$ 14
Additional discount on convertible note					$ 63,060	$ 110,783
Convertible Note 2019 - 07 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock			2,000
Warrants price per share			$ 24
Convertible Note 2019 - 07 [Member] | Minimum [Member]
Convertible notes payable issued		$ 5,000,000
Officer Convertible Note [Member]
Convertible notes payable issued	$ 100,000
Debt instrument, interest rate	14.00%
Debt instrument, maturity date	Jun. 30, 2020
Debt instrument, conversion price	$ 20

Related Party Convertible Not_6

Related Party Convertible Notes Payable - Schedule of Related Party Future Maturities of Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Total	$ 1,050,000	$ 1,050,000
Related Party Convertible Note [Member]
2020	1,132,608
Total	$ 1,132,608

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 29, 2020	Mar. 31, 2020	Mar. 31, 2019
Original issue discount		$ 297,656
Gain on convertible notes	$ 95,888
Interest charges incurred		45,593	$ 19,973
Convertible Note [Member]
Original issue discount		915,964
Interest expense		185,210
Accumulated amortization		150,943
Interest charges incurred		39,426
Interest accrued and payable		$ 31,370

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Total notes payable	$ 1,132,608	$ 1,132,608
Plus amortization of discounts	148,580	295,037
Convertible Note 2019 - 01 [Member]
Total notes payable		150,000
Convertible Note 2019 - 03 [Member]
Total notes payable	108,696	108,696
Convertible Note 2019 - 04 [Member]
Total notes payable	54,348	54,348
Convertible Note 2019 - 05 [Member]
Total notes payable	27,174	27,174
Convertible Note 2019 - 06 [Member]
Total notes payable	27,174	27,174
Convertible Note 2019 - 08 [Member]
Total notes payable	108,696	108,696
Convertible Note 2019 - 09 [Member]
Total notes payable	27,174	27,174
Convertible Note 2019 - 10 [Member]
Total notes payable	16,304	16,304
Convertible Note 2020 - 01 [Member]
Total notes payable	10,870
Convertible Note 2020 - 02 [Member]
Total notes payable	262,500
Convertible Note 2020 - 03 [Member]
Total notes payable	52,631
Convertible Note 2020 - 04 [Member]
Total notes payable	250,000
Convertible Note 2020 - 05 [Member]
Total notes payable	250,000
Convertible Note [Member]
Total notes payable	1,195,567	519,566
Less original issue discounts	(85,567)	(29,566)
Convertible notes payable, net	1,110,000	490,000
Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants	(830,397)	(253,675)
Plus amortization of discounts	150,943	121,964
Total convertible notes payable, net	$ 430,546	358,289
Convertible Note 2020 - 01 [Member]
Total notes payable

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

Mar. 16, 2020

Feb. 25, 2020

Jan. 21, 2020

Jan. 06, 2020

Nov. 08, 2019

Oct. 29, 2019

Oct. 23, 2019

Oct. 10, 2019

Oct. 03, 2019

Sep. 25, 2019

Sep. 04, 2019

Apr. 18, 2019

Apr. 18, 2019

Mar. 31, 2020

Mar. 17, 2020

Feb. 21, 2020

Dec. 31, 2019

Original issue discount

$ 82,608

$ 82,608

Convertible Note 2019 - 01 [Member]

Convertible notes payable issued

$ 150,000

$ 150,000

Debt instrument, interest rate

10.00%

10.00%

Debt instrument, maturity date

Dec. 31, 2019

Debt instrument maturity date, description

Originally matured on December 31, 2019, which was subsequently extended to March 31, 2020.

Debt instrument, conversion price

$ 24

$ 24

Adjusted exercise price per share

$ 4.27

$ 14

Additional discount on convertible note

$ 0

$ 199,012

Convertible Note 2019 - 01 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

2,500

2,500

Warrants price per share

$ 40

$ 40

Note repaid term

Mar. 17, 2020

Convertible Note 2019 - 03 [Member]

Convertible notes payable issued

$ 108,696

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 8,696

Exchange of convertible notes payable

$ 100,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 03 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

1,000

Warrants price per share

$ 24

Additional discount on convertible note

$ 18,326

Convertible Note 2019 - 04 [Member]

Convertible notes payable issued

$ 54,348

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 4,348

Exchange of convertible notes payable

$ 50,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 04 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

500

Warrants price per share

$ 24

Additional discount on convertible note

$ 4,190

Convertible Note 2019 - 05 [Member]

Convertible notes payable issued

$ 27,174

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 2,174

Exchange of convertible notes payable

$ 25,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 05 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 24

Additional discount on convertible note

$ 2,705

Convertible Note 2019 - 06 [Member]

Convertible notes payable issued

$ 27,174

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 2,174

Exchange of convertible notes payable

$ 25,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 06 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 24

Additional discount on convertible note

$ 2,505

Convertible Note 2019 - 08 [Member]

Convertible notes payable issued

$ 108,696

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 8,696

Exchange of convertible notes payable

$ 100,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 08 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 21,363

Convertible Note 2019 - 08 [Member] | Detachable Warrant One [Member]

Warrants to purchase common stock

1,250

Warrants price per share

$ 30

Convertible Note 2019 - 08 [Member] | Detachable Warrant Two [Member]

Warrants to purchase common stock

1,250

Warrants price per share

$ 40

Convertible Note 2019 - 09 [Member]

Convertible notes payable issued

$ 27,174

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 2,174

Exchange of convertible notes payable

$ 25,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 09 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 24

Additional discount on convertible note

$ 2,295

Convertible Note 2019 - 10 [Member]

Convertible notes payable issued

$ 16,304

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 14

Original issue discount

$ 1,304

Exchange of convertible notes payable

$ 15,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 10 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

150

Warrants price per share

$ 14

Additional discount on convertible note

$ 3,279

Convertible Note 2020 - 01 [Member]

Convertible notes payable issued

$ 10,870

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 10

Original issue discount

$ 870

Exchange of convertible notes payable

$ 10,000

Debt instrument, amortized period

36 months

Convertible Note 2020 - 01 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

100

Warrants price per share

$ 10

Additional discount on convertible note

$ 793

Convertible Note 2020 - 02 [Member]

Convertible notes payable issued

$ 262,500

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 4.27

Original issue discount

$ 12,500

Exchange of convertible notes payable

$ 250,000

Common stock issued as commitment fee

5,855

Convertible Note 2020 - 02 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 85,247

Convertible Note 2020 - 03 [Member]

Convertible notes payable issued

$ 52,631

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 7.50

Original issue discount

$ 2,632

Exchange of convertible notes payable

$ 50,000

Debt instrument, amortized period

36 months

Qualifing financing amount

$ 5,000,000

Debt instrument, conversion percentage

25.00%

Convertible Note 2020 - 03 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

500

Warrants price per share

$ 7.50

Additional discount on convertible note

$ 1,985

Convertible Note 2020 - 04 [Member]

Convertible notes payable issued

$ 250,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Sep. 16, 2020

Debt instrument, conversion price

$ 4.50

Original issue discount

$ 20,000

Exchange of convertible notes payable

$ 230,000

Common stock issued as commitment fee

5,000

Debt issuance cost

$ 27,777

Legal expenses

$ 5,000

Debt instrument, description

fully repaid within 6 months of issuance

Convertible Note 2020 - 04 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 343,854

Convertible Note 2020 - 05 [Member]

Convertible notes payable issued

$ 250,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Sep. 16, 2020

Debt instrument, conversion price

$ 4.50

Original issue discount

$ 20,000

Exchange of convertible notes payable

$ 230,000

Common stock issued as commitment fee

5,000

Legal expenses

$ 5,000

Debt instrument, description

fully repaid within 6 months of issuance

Number of common stock shares issued

27,777

Convertible Note 2020 - 05 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 343,854

Convertible Notes Payable - S_3

Convertible Notes Payable - Schedule of Future Maturities of Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Total	$ 1,050,000	$ 1,050,000
Convertible Note [Member]
2020	1,195,567
Total	$ 1,195,167

Derivative Financial Instrume_3

Derivative Financial Instruments (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative liabilities	$ 619,508
Loss on fair value of derivative liabilities	(3,667)
Convertible Notes [Member]
Derivative liabilities	$ 78,200

Derivative Financial Instrume_4

Derivative Financial Instruments - Schedule of Fair Value Assumptions Related to Option Issued (Details)	3 Months Ended
	Mar. 31, 2020USD ($)Vehicle
Derivative liabilities | $	$ 619,508
Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liabilities | $
Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liabilities | $
Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liabilities | $	$ 619,508
Convertible Note [Member] | Expected Dividend Yield [Member]
Derivative liabilities, measurement input	0
Convertible Note [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Derivative liabilities, measurement input	0.17
Convertible Note [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Derivative liabilities, measurement input	1.43
Convertible Note [Member] | Volatility [Member] | Minimum [Member]
Derivative liabilities, measurement input	183
Convertible Note [Member] | Volatility [Member] | Maximum [Member]
Derivative liabilities, measurement input	190
Convertible Note [Member] | Expected Term [Member]
Derivative liabilities, expected term	1 year

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jan. 15, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Reverse stock split	200-for-1 reverse stock split
Sold securities in a self-directed offering, aggregate amount			$ 45,000
Common stock, shares outstanding		762,098		687,564
Self-Directed Stock Issuance [Member] | Existing Stockholders [Member]
Sold securities in a self-directed offering, aggregate amount				$ 245,000
Issuance of stock per share				$ 60
Sale of stock, description of transaction				Each $60 unit consisted of 2 shares of restricted common stock (8,169 shares) and a five-year warrant to purchase 1 share of restricted common stock (4,085 warrant shares) at $40 per share.
Number of restricted common stock				8,169
Warrants to purchase of common stock shares				4,085
Warrants term				5 years
Self-Directed Stock Issuance [Member] | Existing Stockholders [Member] | Restricted Common Stock [Member]
Issuance of stock per share				$ 60

Stock Grants (Details Narrative

Stock Grants (Details Narrative) - USD ($)	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of shares granted during period
Stock-based compensation expense					$ 84,063	$ 86,500
Restricted Common Stock [Member] | Directors [Member]
Number of shares granted during period					3,125	2,303
Stock-based compensation expense					$ 18,750	$ 87,500
Restricted Common Stock [Member] | Consultants [Member]
Number of shares granted during period	187	188	187	188
Stock-based compensation expense					$ 0	$ 6,375
Share price	$ 17.80	$ 25	$ 34	$ 12		$ 34	$ 12

Stock Option Plans (Details Nar

Stock Option Plans (Details Narrative) - shares	Dec. 04, 2018	Feb. 07, 2014	Mar. 31, 2020	Dec. 31, 2019	Jan. 02, 2020	Apr. 16, 2015
Options default term			3 years 3 months 4 days	4 years 1 month 6 days
2014 Equity Compensation Plan [Member]
Number of reserved for future issuance		152,101	279,101
Number of reserved shares increased					27,000
2014 Equity Compensation Plan [Member] | Majority Stockholders [Member]
Number of reserved for future issuance						75,000
2014 Equity Compensation Plan [Member] | Stockholders [Member]
Number of reserved for future issuance	25,000
Reserved shares description	On December 4, 2018, the stockholders of the Company approved an increase in the shares reserved under this plan by an additional 25,000 shares and authorized the annual increase of the shares reserved under this plan on January 1st of each year, at the discretion of the Board of Directors, by up to such number of shares that is equal to four percent (4%) of the shares of common stock issued and outstanding as of December 31st of the previous calendar year.
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member]
Options default term		10 years
Option vested term		4 years
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value		100.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | 10% Stockholder [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value		110.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees, Directors, Advisors and Consultants [Member] | Maximum [Member] | Non-statutory Stock Options and Restricted Stock [Member]
Percentage price per share of options granted of fair market value		100.00%

Stock Option Plans - Schedule o

Stock Option Plans - Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning balance	202,246	202,537
Options Exercisable, Beginning balance	192,108	185,837
Options, Canceled		(291)
Options, Granted
Options, Exercised
Options, Forfeited
Options Outstanding, Ending balance	202,246	202,246
Options Exercisable, Ending balance	193,513	192,108
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 80.14	$ 80.13
Weighted Average Exercise Price, Exercisable, Beginning balance	81.32	82.13
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending balance	80.14	80.14
Weighted Average Exercise Price, Exercisable, Ending balance	$ 81.32	$ 81.32
Weighted Average Remaining Contractual Term in Years, Outstanding Beginning	3 years 6 months 7 days	4 years 6 months 7 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Beginning	3 years 3 months 4 days	4 years 1 month 6 days
Weighted Average Remaining Contractual Term in Years, Outstanding Ending	3 years 3 months 8 days	3 years 6 months 7 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Ending	3 years 18 days	3 years 3 months 4 days
Aggregate Intrinsic Value, Outstanding Beginning balance		$ 987,064
Aggregate Intrinsic Value, Exercisable Beginning balance		967,064
Aggregate Intrinsic Value, Outstanding Ending balance
Aggregate Intrinsic Value, Exercisable Ending balance

Stock Option Plans - Schedule_2

Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Non-vested, Options Outstanding, Beginning balance	10,138	16,700
Non-vested, Options Granted
Non-vested, Options Vested	(1,425)	(6,271)
Non-vested, Options Canceled		(291)
Non-vested, Options Outstanding, Ending balance	8,733	10,138

Stock Option Plans - Schedule_3

Stock Option Plans - Schedule of Fair Value Assumptions (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Dividend yield	0.00%	0.00%
Risk-free rate, minimum	2.38%	2.38%
Risk-free rate, maximum	3.04%	3.04%
Expected volatility, minimum	214.00%	214.00%
Expected volatility, Maximum	226.00%	226.00%
Minimum [Member]
Expected term	3 years	3 years
Maximum [Member]
Expected term	7 years	7 years

Stock Option Plans - Schedule_4

Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Service provider compensation	$ 44,375	$ 44,375
Employee compensation	39,688	42,125
Total	$ 84,063	$ 86,500

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Discount on convertible notes	$ 82,608		$ 82,608
Stock compensation expense	84,063	$ 86,500
Warrant [Member]
Stock compensation expense	$ 75,000
Warrants expired	83,068		94,577
Convertible Note Warrants [Member]
Warrants to purchase of common stock shares	600		16,900
Warrants, term	5 years
Discount on convertible notes	$ 69,498		$ 125,545
Convertible Note Warrants [Member] | Directors [Member]
Warrants to purchase of common stock shares	12,756
Warrant price per share	$ 6
Convertible Note Warrants [Member] | Minimum [Member]
Warrant price per share	7.50		$ 14
Convertible Note Warrants [Member] | Maximum [Member]
Warrant price per share	$ 10		$ 40

Warrants - Schedule of Stock Wa

Warrants - Schedule of Stock Warrants Activity (Details) - Warrant [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Warrants, Outstanding, Beginning balance	516,748	590,340
Warrants Exercisable, Beginning balance	516,748	590,340
Warrants, Canceled
Warrants, Granted	13,356	20,985
Warrants, Exercised
Warrants, Expired	(83,068)	(94,577)
Warrants, Outstanding, Ending balance	447,036	516,748
Warrants Exercisable, Ending balance	447,036	516,748
Weighted Average Exercise Price, Outstanding, Beginning	$ 24.60	$ 40.65
Weighted Average Exercise Price, Exercisable, Beginning	24.60	40.65
Weighted Average Exercise Price, Canceled/Expired
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending	23.81	24.60
Weighted Average Exercise Price, Exercisable, Ending	$ 23.81	$ 24.60
Weighted Average Remaining Contractual Term in Years, Beginning Outstanding	1 year 10 months 10 days	2 years 3 months 26 days
Weighted Average Remaining Contractual Term in Years, Beginning Exercisable	1 year 10 months 10 days	2 years 3 months 26 days
Weighted Average Remaining Contractual Term in Years, Ending Outstanding	2 years 1 month 24 days	1 year 10 months 10 days
Weighted Average Remaining Contractual Term in Years, Ending Exercisable	2 years 1 month 24 days	1 year 10 months 10 days
Aggregate Intrinsic Value, Outstanding, Beginning		$ 7,846,743
Aggregate Intrinsic Value, Exercisable, Beginning		7,846,743
Aggregate Intrinsic Value, Outstanding, Ending
Aggregate Intrinsic Value, Exercisable, Ending

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Effective tax statutory rate	21.00%	21.00%

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss (numerator) Basic loss per share, basic	$ (1,002,868)	$ (135,420)
Net loss (numerator) Effect of dilutive securities-Common stock options, warrants, and convertible note
Net loss (numerator) Diluted loss per share, diluted	$ (1,002,868)	$ (135,420)
Shares (Denominator) Basic loss per shares, basic	700,879	670,260
Shares (Denominator) Effect of dilutive securities-Common stock options, warrants, and convertible note
Shares (Denominator) Diluted loss per shares, diluted	700,879	670,260
Per share amount Basic loss per share, basic	$ (1.43)	$ (1.69)
Per share amount Effect of dilutive securities-Common stock options, warrants, and convertible note
Per share amount Diluted loss per share, diluted	$ (1.43)	$ (1.69)

Basic and Diluted Net Loss Pe_4

Basic and Diluted Net Loss Per Share - Schedule of Shares of Common Stock Equivalents Were Excluded from the Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total common stock equivalents excluded from the computation of diluted net loss per share	1,092,692	701,578
Common Stock Convertible Notes [Member]
Total common stock equivalents excluded from the computation of diluted net loss per share	443,410
Common Stock Warrants [Member]
Total common stock equivalents excluded from the computation of diluted net loss per share	447,036	499,041
Common Stock Options [Member]
Total common stock equivalents excluded from the computation of diluted net loss per share	202,246	202,537

Leases (Details Narrative)

Leases (Details Narrative)	Aug. 30, 2019USD ($)	Jan. 31, 2018USD ($)Vehicle	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Aug. 13, 2010
Operating lease, right-to-use asset			$ 9,606		$ 12,488
ASU No. 2016-02 [Member]
Operating lease, right-to-use asset			9,606	$ 30,813
Operating lease, liabilities			9,606	30,813
Manoa Innovation Center [Member]
Lease, term						45 days
Rent expenses			8,989	9,100
Vehicle Lease Arrangement [Member]
Lease, term		3 years
Number of vehicles | Vehicle		3
Total monthly payment	$ 1,002	$ 1,619
Lease expense			$ 3,745	$ 5,959

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 14, 2020	Apr. 22, 2020	Mar. 16, 2020	Mar. 31, 2020	Mar. 31, 2019
Original issue discount				$ 297,656
Common stock grant to convertible note holders				$ 434,712
Convertible Note 2020 - 04 [Member]
Debt instrument, description			fully repaid within 6 months of issuance
Debt instrument interest rate			10.00%
Debt instrument, convertible, conversion price			$ 4.50
Subsequent Event [Member]
Debt instrument, description		On April 22, 2020, the Company received a PPP loan for $211,300. Under the terms of the program, up to 100% of the loan amount may be forgiven if certain terms and conditions are met. The unforgiven amount, if any, matures in April 2022 and accrues interest at 1% per annum with principal and interest payments starting in November 2020.
Proceeds from loans		$ 211,300
Debt instrument interest rate		1.00%
Subsequent Event [Member] | Convertible Promissory Notes [Member]
Debt instrument interest rate	10.00%
Convertible note payable	$ 500,000
Original issue discount	40,000
Common stock grant to convertible note holders	$ 460,000
Debt instrument, convertible, conversion price	$ 9.75
Common stock grant to convertible note holders, shares	10,000
Subsequent Event [Member] | Convertible Note 2020 - 04 [Member]
Extinguishment of debt, amount	$ 250,000